<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01199874</url>
  </required_header>
  <id_info>
    <org_study_id>PATH HS534</org_study_id>
    <nct_id>NCT01199874</nct_id>
  </id_info>
  <brief_title>Immunogenicity of Rotavirus Vaccine</brief_title>
  <official_title>The Immunogenicity of Rotavirus Vaccine Under Different Age Schedules and the Impact of Withholding Breast Feeding Around the Time of Vaccination on the Immunogenicity of Rotarix Vaccine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PATH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PATH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rotavirus is one of the most common causes of severe diarrhea, responsible for 40% of all
      diarrhea related deaths in children worldwide. Two vaccines against Rotavirus, Rotarix速 and
      Rotateq速 were licensed in many high and middle income countries in 2006, but lack of efficacy
      data in low income countries had prevented WHO from making a universal recommendation of
      their use until recently. This study will be conducted in Pakistan and will look at two
      objectives:

        1. To compare the immunogenicity of Rotarix速 vaccine when administered at 6 and 10 weeks of
           life and at 6, 10 and 14 weeks of life.

        2. To compare the immunogenicity of Rotarix速 vaccine in infants breast fed at the time of
           vaccine administration with infants whose breast feeding is withheld for one hour before
           and after vaccine administration.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seropositivity as anti-rotavirus IgA concentration &gt;/= 20 U/ml</measure>
    <time_frame>6, 10, 14 and 18 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">1140</enrollment>
  <condition>Rotavirus Gastroenteritis</condition>
  <arm_group>
    <arm_group_label>Primary 1: Rotavirus vaccine 6 and 10 weeks</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EPI vaccines + rotavirus vaccine at 6 and 10 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Primary 1: Rotavirus vaccine 6, 10 and 14 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EPI vaccines + rotavirus vaccine at 6, 10 and 14 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Primary 1: Rotavirus vaccine 10 and 14 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EPI vaccines + rotavirus vaccine at 10 and 14 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Primary 2: Rotavirus vaccine withholding breast feeding</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EPI vaccines + rotavirus vaccine at 6, 10 and 14 weeks withholding breastfeeding</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Primary 2: Rotavirus vaccine with immediate breast feeding</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EPI vaccines + rotavirus vaccine at 6, 10 and 14 weeks with immediate breastfeeding</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Baseline seroconversion for rotavirus</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>EPI vaccines</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rotavirus vaccine</intervention_name>
    <description>live attenuated oral rotavirus vaccine; lyophilized; 1 ml</description>
    <arm_group_label>Primary 1: Rotavirus vaccine 6 and 10 weeks</arm_group_label>
    <arm_group_label>Primary 1: Rotavirus vaccine 6, 10 and 14 weeks</arm_group_label>
    <arm_group_label>Primary 1: Rotavirus vaccine 10 and 14 weeks</arm_group_label>
    <arm_group_label>Primary 2: Rotavirus vaccine withholding breast feeding</arm_group_label>
    <arm_group_label>Primary 2: Rotavirus vaccine with immediate breast feeding</arm_group_label>
    <other_name>Rotarix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  6 weeks 0 days to 6 weeks 6 days age at the time of enrollment.

          -  Healthy infant free of chronic or serious medical condition as determined by history
             and physical exam at time of enrollment into in the study.

          -  Written informed consent obtained from the parents or guardians.

        Exclusion Criteria:

          -  Hypersensitivity to any of the vaccine components.

          -  Use of any investigational drug or vaccine other than the study vaccine within 30 days
             of first dose of study vaccine or during the study.

          -  Use of any immunosuppressive drugs.

          -  Previous intussusception or abdominal surgery.

          -  Enrolment in any other trial (Simplified Antibiotic Therapy for Neonatal Sepsis Trial,
             Management of Omphalitis Trial).

          -  Birth weight less than 1500 grams; or if birth weight is unknown, weight less than
             2000 grams on or before 28 days.

          -  Immunoglobulin and/or blood products use since birth or during the study period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>18 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>S. Asad Ali, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aga Khan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aga Khan University</name>
      <address>
        <city>Karachi</city>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2010</study_first_submitted>
  <study_first_submitted_qc>September 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2010</study_first_posted>
  <last_update_submitted>August 28, 2013</last_update_submitted>
  <last_update_submitted_qc>August 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rotavirus</keyword>
  <keyword>Rotavirus vaccine</keyword>
  <keyword>Dosing schedule</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>Breast feeding</keyword>
  <keyword>Pakistan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroenteritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

